Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Showing 1737 results
September 2023
-
Media ReleaseSandoz receives European Commission approval for Tyruko® (natalizumab), first and only biosimilar for multiple sclerosis in EuropeBiosimilar Tyruko® approved for all indications of reference medicine, as first and only biosimilar to treat relapsing forms of multiple sclerosis (MS) in EuropeDecision based on evidence from…
-
Media ReleaseNovartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)Phase III NETTER-2 trial met primary endpoint of improvement in progression-free survival (PFS) and key secondary endpoint of objective response rate (ORR) in patients with Grade 2 and 3 advanced…
-
Media ReleaseNovartis confirms Sandoz Spin-off for October 4, 2023Sandoz shares (SDZ) to be listed and traded on SIX Swiss Exchange; ADRs to be traded on OTCQX®, first trading day October 4, 2023Sandoz to be included in key Swiss market indicesInvestment grade…
-
StatementNovartis statement on collaboration and license agreement for tislelizumab with BeiGene, Ltd.
Novartis and BeiGene, Ltd. have mutually agreed to terminate the collaboration and license agreement for tislelizumab, a humanized IgG4 anti-PD-1 monoclonal antibody.
-
Media ReleaseSandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumabPositive CHMP opinion based on comprehensive package of analytical, pre-clinical and clinical dataBreast and gastric cancers are among most common types of cancer, accounting together for nearly half…
-
Media ReleaseNovartis shareholders approve the proposed 100% Spin-off of SandozShareholders approve the proposed 100% Spin-off of Sandoz, the Generics and Biosimilars business of NovartisShareholders also approve a reduction of share capital in connection with the Spin-off…
-
Media ReleaseLes actionnaires de Novartis approuvent le projet de scission à 100% de SandozLes actionnaires approuvent le projet de scission à 100% de Sandoz, l’activité Génériques et Biosimilaires de NovartisLes actionnaires approuvent également une réduction du capital social dans le…
-
Media ReleaseAktionärinnen und Aktionäre von Novartis stimmen dem geplanten 100% igen Spin-off von Sandoz zuDie Aktionärinnen und Aktionäre stimmen dem geplanten 100%igen Spin-off von Sandoz, dem Generika- und Biosimilars-Geschäft von Novartis, zu.Die Aktionärinnen und Aktionäre stimmen ausserdem einer…
-
Media ReleaseNovartis Kisqali® reduced the risk of cancer recurrence while maintaining quality of life in patients diagnosed with early breast cancerPatient-reported outcomes (PROs) from the Phase III NATALEE trial show that patients receiving adjuvant Kisqali plus endocrine therapy (ET) for up to three years maintained physical and social…
-
StatementNovartis provides support for Moroccan earthquake victims
-
Featured NewsNovartis’ Giving & Volunteering wins ACCP’s 2023 Corporate Social Impact Team of the Year Award
-
StatementGT005 (PPY988): Development Program in Geographic Atrophy